{"id":"https://openalex.org/W7224845025","doi":"https://doi.org/10.3389/fmed.2026.1938709","title":"Companion diagnostics and clinical drug development in oncology: a survey based on US FDA data","display_name":"Companion diagnostics and clinical drug development in oncology: a survey based on US FDA data","publication_year":2026,"publication_date":"2026-10-30","ids":{"openalex":"https://openalex.org/W7224845025","doi":"https://doi.org/10.3389/fmed.2026.1938709"},"language":"en","primary_location":{"id":"doi:10.3389/fmed.2026.1938709","doi":"https://doi.org/10.3389/fmed.2026.1938709","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fmed.2026.1938709","pdf_url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1938709/pdf","source":{"id":"https://openalex.org/S2597052008","display_name":"Frontiers in Medicine","issn_l":"2296-858X","issn":["2296-858X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1938709/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016294354","display_name":"Jan Tr\u00f8st J\u00f8rgensen","orcid":"https://orcid.org/0000-0001-6255-0006","observed_orcids":["https://orcid.org/0000-0001-6255-0006"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jan Tr\u00f8st J\u00f8rgensen","raw_affiliation_strings":["Medical Science, Dx-Rx Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Science, Dx-Rx Institute","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5016294354"],"corresponding_institution_ids":[],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.83085152,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"13","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.2287999987602234,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.2287999987602234,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.1307000070810318,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.10580000281333923,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/companion-diagnostics","display_name":"companion diagnostics","score":0.9990000128746033},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7089999914169312},{"id":"https://openalex.org/keywords/anticancer-drug-development","display_name":"anticancer drug development","score":0.8999999761581421},{"id":"https://openalex.org/keywords/kinase-inhibitors","display_name":"kinase inhibitors","score":0.800000011920929},{"id":"https://openalex.org/keywords/orphan-drug-designation","display_name":"orphan drug designation","score":0.6869999766349792},{"id":"https://openalex.org/keywords/breakthrough-therapy-designation","display_name":"breakthrough therapy designation","score":0.9020000100135803},{"id":"https://openalex.org/keywords/clinical-trial-design","display_name":"clinical trial design","score":0.5669999718666077},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7680000066757202},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9710000157356262},{"id":"https://openalex.org/keywords/drug-safety-assessment","display_name":"drug safety assessment","score":0.5820000171661377},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.8799999952316284}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8855000138282776},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.7360000014305115},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6739000082015991},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.6578999757766724},{"id":"https://openalex.org/C502991105","wikidata":"https://www.wikidata.org/wiki/Q5133849","display_name":"Clinical research","level":2,"score":0.5281000137329102},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.515500009059906},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4903999865055084},{"id":"https://openalex.org/C2777494893","wikidata":"https://www.wikidata.org/wiki/Q4781752","display_name":"Approved drug","level":3,"score":0.46399998664855957},{"id":"https://openalex.org/C2992293740","wikidata":"https://www.wikidata.org/wiki/Q4781752","display_name":"Drug approval","level":3,"score":0.4519999921321869},{"id":"https://openalex.org/C75480439","wikidata":"https://www.wikidata.org/wiki/Q1367466","display_name":"Orphan drug","level":2,"score":0.44850000739097595},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4481000006198883},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43779999017715454},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4339999854564667},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3959999978542328},{"id":"https://openalex.org/C2780416959","wikidata":"https://www.wikidata.org/wiki/Q22907415","display_name":"Companion diagnostic","level":3,"score":0.38029998540878296},{"id":"https://openalex.org/C149172746","wikidata":"https://www.wikidata.org/wiki/Q2585693","display_name":"Efficacy","level":3,"score":0.3693000078201294},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.35519999265670776},{"id":"https://openalex.org/C148482608","wikidata":"https://www.wikidata.org/wiki/Q17007018","display_name":"Clinical study design","level":3,"score":0.3499000072479248},{"id":"https://openalex.org/C3020340455","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Cancer drugs","level":3,"score":0.3407999873161316},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.33980000019073486},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31929999589920044},{"id":"https://openalex.org/C188313352","wikidata":"https://www.wikidata.org/wiki/Q119697","display_name":"Off-label use","level":2,"score":0.3172999918460846},{"id":"https://openalex.org/C2776598537","wikidata":"https://www.wikidata.org/wiki/Q1812651","display_name":"Clinical Oncology","level":3,"score":0.3165999948978424},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.3158000111579895},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.3091000020503998},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.30820000171661377},{"id":"https://openalex.org/C3018146709","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Anticancer drug","level":3,"score":0.29030001163482666},{"id":"https://openalex.org/C163763905","wikidata":"https://www.wikidata.org/wiki/Q17075943","display_name":"Precision medicine","level":2,"score":0.2863999903202057},{"id":"https://openalex.org/C19527891","wikidata":"https://www.wikidata.org/wiki/Q1120908","display_name":"Medical physics","level":1,"score":0.2856000065803528},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2833000123500824},{"id":"https://openalex.org/C56666940","wikidata":"https://www.wikidata.org/wiki/Q788790","display_name":"Documentation","level":2,"score":0.2808000147342682},{"id":"https://openalex.org/C2992053201","wikidata":"https://www.wikidata.org/wiki/Q2585693","display_name":"Clinical efficacy","level":2,"score":0.2734000086784363},{"id":"https://openalex.org/C2776876202","wikidata":"https://www.wikidata.org/wiki/Q1368197","display_name":"New drug application","level":3,"score":0.27090001106262207},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.26969999074935913}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fmed.2026.1938709","doi":"https://doi.org/10.3389/fmed.2026.1938709","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fmed.2026.1938709","pdf_url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1938709/pdf","source":{"id":"https://openalex.org/S2597052008","display_name":"Frontiers in Medicine","issn_l":"2296-858X","issn":["2296-858X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Medicine","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:55d4d7cf8e784301896eaa3d3906cfc4","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/55d4d7cf8e784301896eaa3d3906cfc4","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Medicine, Vol 13 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fmed.2026.1938709","doi":"https://doi.org/10.3389/fmed.2026.1938709","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fmed.2026.1938709","pdf_url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1938709/pdf","source":{"id":"https://openalex.org/S2597052008","display_name":"Frontiers in Medicine","issn_l":"2296-858X","issn":["2296-858X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7224845025.pdf","grobid_xml":"https://content.openalex.org/works/W7224845025.grobid-xml"},"referenced_works_count":12,"referenced_works":["https://openalex.org/W1991601855","https://openalex.org/W2097395369","https://openalex.org/W2098771462","https://openalex.org/W2127405377","https://openalex.org/W2161630562","https://openalex.org/W2262115948","https://openalex.org/W2318605753","https://openalex.org/W2773809764","https://openalex.org/W3186354807","https://openalex.org/W4381839562","https://openalex.org/W4396622724","https://openalex.org/W7117976016"],"related_works":["https://openalex.org/W4283029777","https://openalex.org/W2903699524","https://openalex.org/W2912544526","https://openalex.org/W2524013739","https://openalex.org/W2075727223","https://openalex.org/W2592909536","https://openalex.org/W3135988286","https://openalex.org/W4414523441","https://openalex.org/W7137854799","https://openalex.org/W3138148523"],"abstract_inverted_index":{"Over":[0],"the":[1,5,31,44,47,62,79,82,128,141,187,216,220,237],"past":[2],"few":[3],"decades,":[4],"drug-diagnostic":[6],"codevelopment":[7],"model":[8],"has":[9,42],"gradually":[10],"transformed":[11],"oncology":[12,70],"drug":[13,40,63,89,130],"development.":[14],"In":[15,67],"this":[16,68,107],"model,":[17],"a":[18,24,74],"predictive":[19],"biomarker":[20],"assay,":[21],"known":[22],"as":[23],"companion":[25],"diagnostic":[26],"(CDx),":[27],"is":[28,233],"developed":[29],"alongside":[30],"drug.":[32],"The":[33,154,199],"incorporation":[34],"of":[35,46,65,84,114,122,140,186,222],"CDx":[36,75],"assays":[37],"in":[38,51,202],"clinical":[39,91,181,197,227],"development":[41],"facilitated":[43],"use":[45],"enrichment":[48,217],"trial":[49,92,218],"design,":[50,93,219,240],"which":[52,115,241],"patients":[53,223],"are":[54],"selected":[55],"based":[56,170,193],"on":[57,171,194],"molecular":[58],"characteristics":[59],"linked":[60],"to":[61,159,225,236],"mechanism":[64],"action.":[66],"survey,":[69],"drugs":[71,111,135,142,168],"associated":[72],"with":[73,165],"assay":[76],"approved":[77,169],"by":[78,178],"FDA":[80,161,231],"until":[81],"end":[83],"2025":[85],"were":[86,104,112,118,127],"investigated,":[87],"and":[88,101,149,211,229],"class,":[90,131],"study":[94],"endpoint,":[95],"patient":[96,156],"population,":[97],"Orphan":[98,145],"Drug":[99,146],"status,":[100],"expedited":[102],"review":[103],"recorded.":[105],"During":[106],"period,":[108],"87":[109],"cancer":[110],"identified,":[113],"62":[116],"(71%)":[117],"indicated":[119],"for":[120,133],"treatment":[121],"solid":[123],"tumors.":[124],"Kinase":[125],"inhibitors":[126],"dominant":[129],"accounting":[132],"34":[134],"(55%).":[136],"A":[137],"large":[138],"proportion":[139],"had":[143],"obtained":[144],"status":[147],"(63%)":[148],"Breakthrough":[150],"Therapy":[151],"designation":[152],"(77%).":[153],"average":[155],"population":[157],"sufficient":[158],"obtain":[160,230],"approval":[162,232],"was":[163,191,205],"279,":[164],"16":[166],"(26%)":[167],"fewer":[172],"than":[173],"100":[174],"patients,":[175],"often":[176,207],"supported":[177],"single-arm,":[179],"open-label":[180],"trials.":[182],"For":[183],"49":[184],"(79%)":[185],"drugs,":[188],"efficacy":[189,228],"documentation":[190],"generated":[192],"one":[195],"single":[196],"trial.":[198],"primary":[200],"endpoint":[201],"these":[203],"trials":[204],"most":[206],"objective":[208],"response":[209],"rate":[210],"progression-free":[212],"survival.":[213],"When":[214],"evaluating":[215],"number":[221],"required":[224],"demonstrate":[226],"low":[234],"compared":[235],"traditional":[238],"all-comers":[239],"means":[242],"that":[243],"safety":[244],"evaluation":[245],"could":[246],"be":[247],"compromised.":[248]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2026-10-31T00:00:00"}